KINTOR PHARMA-B(09939) achieved sales revenue of approximately 34 million yuan this year, exceeding the total sales revenue of last year.

KINTOR PHARMA-B (09939) announced that since the beginning of 2026, the company's B2C and B2B sales have been growing rapidly and steadily. According to the company's preliminary statistics, as of the date of this announcement, the accumulated sales revenue for this year has already exceeded the total sales revenue for the full year of 2025. As of the date of this announcement, the company's sales revenue for this year has reached approximately 34 million RMB, surpassing last year's total sales revenue of 32.68 million RMB. It is expected to exceed the target of surpassing 150 million RMB for the full year, with the main components including B2C domestic e-commerce sales, overseas e-commerce sales, and B2B raw material sales. In the B2C domestic e-commerce sector, the sales revenue for the first quarter of this year has grown 25 times compared to the same period last year. In particular, the company's self-owned sales business has continued to grow since its launch five months ago, with an average daily sales amounting to nearly 100,000 RMB this month and achieving a record single-day gross merchandise volume (GMV) of 400,000 RMB. In the B2C overseas e-commerce sector, the sales revenue for the first quarter of this year has increased by 150% compared to the same period last year. In the B2B raw material sales sector, the sales revenue for the first quarter of this year was 3.44 million RMB, while last year's sales were zero, also far exceeding the total sales revenue for last year. The company plans to use the cash flow generated from its cosmetics products and raw material business to provide funding support for the development and commercialization (listing business) of the company's core products KX-826, GT20029, and other pipeline products. At the same time, the company will continue to adhere to its established principles in its listed business.